il15-transpresenting wt1-targeted dendritic cell vaccine
Esophageal Cancer
Explore 131 assets in Esophageal Cancer →Floatz Rating
CC44/100
Confidence
Indicative
Sponsor
University Hospital, Antwerp
Modality
vaccine
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05964361CT.gov First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Esophageal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| il15-transpresenting wt1-targeted dendritic cell vaccine (this asset) | University Hospital, Antwerp | P1/2 | CC · 44 |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
| Fluorouracilum | Merck Sharp & Dohme LLC | P4 | BB |
| Pembrolizumab | Essen Biotech | P3 | B |
| Epirubicin | Sutro Biopharma, Inc. | P3 | B |
| Cetirizine | Ciusss de L'Est de l'Île de Montréal | P3 | B |
| Capecitabine | Shenyang Sunshine Pharmaceutical Co., LTD. | P2 | B |
| Carboplatin | Neonc Technologies, Inc. | P2 | B |
| Cyclophosphamide | Sutro Biopharma, Inc. | P3 | B |
+42 more in the Esophageal Cancer cohort
Other indications for il15-transpresenting wt1-targeted dendritic cell vaccine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Pancreatic Neoplasm | — | P1/2 | CC · 46 |
| Liver Cancer | — | P1/2 | CC · 44 |
| Ovarian Cancer | — | P1/2 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. il15-transpresenting wt1-targeted dendritic cell vaccine in Esophageal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/il15-transpresenting-wt1-targeted-dendritic-cell-vaccine-esophageal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →